Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M203610200 on May 23, 2002

J. Biol. Chem., Vol. 277, Issue 31, 27903-27911, August 2, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/31/27903    most recent
M203610200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seshadri, V.
Right arrow Articles by Mukhopadhyay, C. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seshadri, V.
Right arrow Articles by Mukhopadhyay, C. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Dual Role of Insulin in Transcriptional Regulation of the Acute Phase Reactant Ceruloplasmin*

Vasudevan SeshadriDagger , Paul L. FoxDagger §, and Chinmay K. MukhopadhyayDagger

From the Dagger  Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195 and the  Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi 110 067, India

Received for publication, April 15, 2002, and in revised form, May 22, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Insulin is a potent negative regulator of the response of hepatic cells to pro-inflammatory cytokines, particularly, interleukin (IL)-6. The action of insulin is target-selective because it inhibits transcription of most but not all acute phase genes. We here show that ceruloplasmin (Cp), an acute phase reactant with important functions in iron homeostasis, is subject to a unique dual regulation by insulin. IL-6 increased Cp mRNA expression in HepG2 cells by ~5-fold. Simultaneous treatment with insulin reduced this stimulation by half. Surprisingly, insulin by itself caused a 2-4-fold induction in Cp mRNA expression. The mechanism of induction by insulin was studied by transfecting into HepG2 cells chimeric constructs of the Cp 5'-flanking region driving luciferase. The activity of a 4800-bp segment of the Cp 5'-flanking region was increased 3-fold by insulin. Deletion and mutation analyses showed the requirement for a single hypoxia-responsive element in a 96-bp segment ~3600 bp upstream of the initiation site. The domains required for the two activities of insulin were distinct: The distal, hypoxia-responsive element-containing site was sufficient for Cp transactivation by insulin; in contrast, an 848-bp region adjacent to the initiation site was sufficient for IL-6 transactivation of Cp and for the inhibitory activity of insulin. The role of hypoxia-inducible factor-1 in the induction of Cp by insulin was shown by electrophoretic mobility shift assays and by the absence of insulin-stimulated Cp promoter activation in mouse Hepa c4 cells deficient in hypoxia-inducible factor-1 activity. Taken together these results show that insulin functions as a bidirectional, condition-dependent regulator of hepatic cell Cp expression. The unique regulation of Cp may reflect its dual roles in inflammation and iron homeostasis.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Vertebrates respond to tissue damage and other inflammatory stimuli by implementing a coordinated series of processes known as the acute phase reaction. A characteristic of this response, and the basis of common clinical tests, is the increase in the plasma concentration of a limited group of proteins, e.g. C-reactive protein. The major function of the acute phase response is almost certainly to protect the host against injury, trauma, infection, and other inflammatory events (1, 2). The response is initiated by surveying leukocytes that respond to these events by secretion of inflammatory mediators. These mediators have been broadly classified into two groups: (i) cytokines, such as interleukin (IL)1-6, IL-1, interferon-gamma , and tumor necrosis factor-alpha , which are the primary regulators of acute phase gene expression; and (ii) insulin (and other growth factors) and glucocorticoids, which function as modulators of cytokine action (1, 2). Among the pro-inflammatory mediators, IL-6 is considered to be the major physiological regulator of acute phase gene expression (2, 3). The liver is a principal target of inflammatory mediators, and the specific actions of these mediators with respect to the pattern of acute phase gene expression have been defined in detail in hepatocarcinoma cell lines (2). Insulin is a highly effective negative regulator of the cytokine-stimulated acute phase response in vitro (4-8) and in vivo (9, 10). Insulin inhibits IL-6-mediated induction of haptoglobin, thiostatin, complement C3, and C-reactive protein in hepatocytes and HepG2 cells (6, 11). The extent of the inhibition depends on the target protein, and insulin does not alter IL-6-induced expression of several acute phase proteins including alpha 1-antichymotrypsin and alpha 1-acid glycoprotein (6, 11).

Ceruloplasmin (Cp) is a 132-kDa, copper-containing acute phase protein of mainly hepatic origin. Its plasma concentration during inflammation in humans increases by ~50-100%, much less than the 100-1000-fold increases for C-reactive protein and serum amyloid A (12). The function of Cp during inflammation is unclear. Several groups have reported an antioxidant activity of Cp that protects lipids and DNA against free radical-mediated injury (13). In contrast, we and others have shown that Cp copper can cause oxidative modification of lipoproteins (14-16). In addition to its participation in free radical reactions, Cp is an important regulator of iron homeostasis. It is the major ferroxidase in plasma, catalyzing the conversion of Fe2+ to Fe3+ for binding by apo-transferrin (17). The key role of Cp in iron homeostasis is supported by recent reports of iron overload in patients with hereditary Cp deficiency (18), and in mice with targeted disruption of the Cp gene (19). These findings, together with early organ culture and animal studies (20, 21), suggest that Cp is required for efficient release of iron from cells and tissues. In contrast, Cp has been shown to mediate inward iron flux as well in some cell culture systems. Cp increases iron uptake by iron-deficient cells of hepatic and erythroid origin (22, 23), and by glioblastoma cells (24, 25); the Cp homologue fet3p has a similar role in high affinity iron uptake in Saccharomyces cerevisiae (26, 27).

The spectrum of agents that increases plasma Cp concentration in vivo, and hepatic cell synthesis of Cp in vitro, is consistent with its involvement in both inflammation as well as iron homeostasis. Plasma levels of Cp increase in animal models of inflammation, including after injection of tumor necrosis factor-alpha , turpentine, IL-6, and endotoxin (28-30). Cp secretion is increased in human hepatoma cells exposed to IL-6 (31, 32), but the underlying molecular mechanism has not been investigated in detail; a recent report suggests that regulation may be post-transcriptional (33). We have shown recently that iron depletion increases hepatic cell transcription of Cp via activation of hypoxia-inducible factor (HIF)-1, which binds to a hypoxia-responsive element (HRE) in the 5'-flanking region of Cp (22, 34). HIF-1 is a heterodimer containing HIF-1alpha and HIF-1beta /aryl hydrocarbon receptor nuclear translocator (ARNT) subunits, two basic helix-loop-helix/Per-ARNT-Sim proteins (35). Upon cell activation, HIF-1alpha is induced and it translocates to the nucleus where it forms dimers with HIF-1beta ; these dimers bind to HREs in multiple genes to induce transcription. HIF-1 is activated by iron deficiency, hypoxia, and CoCl2, and recent evidence shows activation of HIF-1 by insulin and insulin-like growth factor (36, 37). Thus, HIF-1 activation may provide a common mechanism for induction of multiple genes by hypoxia and insulin, e.g. erythropoietin, vascular endothelial growth factor, and the glucose transporter Glut1 (36, 38).

The known transcriptional responses of Cp present a potential paradox regarding the effect of insulin on Cp gene expression. As a negative regulator of the acute phase response, insulin would be expected to diminish transcriptional activation of Cp, particularly by IL-6. In contrast, as a HIF-1-responsive protein, insulin may increase Cp expression. To investigate this paradox, we have studied the effect of insulin (and IL-6) on the transcriptional response of Cp in HepG2 cells. Like multiple other acute phase proteins, the IL-6-mediated induction of Cp is inhibited by insulin. However, our results indicate that Cp is unique among acute phase proteins in that transcription is induced by insulin, in the absence of IL-6, through HIF-1 activation. This unusual dual response of Cp to insulin may be the result of its unique metabolic positioning at the intersection of inflammation and iron metabolism.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents-- Human Cp was purchased from Calbiochem and bovine insulin from Invitrogen. Rabbit polyclonal anti-human Cp IgG and peroxidase-conjugated anti-rabbit IgG were obtained from Accurate Chemical (Westbury, NY) and Roche Molecular Biochemicals, respectively. Other reagents were from Sigma.

Cell Lines and Culture Conditions-- Human hepatocarcinoma HepG2 cells were obtained from American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine (Invitrogen). Mouse hepatoma cell lines Hepa-1c1c7 and Hepa c4 were kind gifts of Oliver Hankinson and were cultured in modified Eagle's medium with the same supplements used for HepG2 cells. Cells at 50-60% confluence were used in all experiments. Cells were maintained in a humidified atmosphere containing 5% CO2 at 37 °C. For experiments in which cells were exposed to hypoxia, oxygen tension in the chamber (Billups-Rothenberg, San Diego, CA) was set at either 1% O2 for hypoxia or 20% O2 for normoxia.

Immunoblot Analysis of Cp-- Conditioned medium from serum-deprived HepG2 cells was subjected to 7% SDS-PAGE using Protogel (National Diagnostics, Atlanta, GA) and transferred by a semi-dry method to an Immobilon-P membrane (Millipore, Bedford, MA). The membrane was incubated with anti-human Cp IgG (1:10,000) as primary antibody, and then with peroxidase-conjugated secondary antibody (1:5000). Cp was detected by chemiluminescence using ECL (Amersham Biosciences). The blot was subsequently incubated with Coomassie Blue dye to verify uniform loading of all samples.

RNA Blot Analysis of Cp and Other Transcripts-- RNA was isolated from HepG2 cells using TRIzol reagent (Invitrogen). Total RNA (20 µg) was denatured in formamide/formaldehyde, electrophoresed through a 1% agarose gel containing 6% formaldehyde, and then blotted onto nylon membranes (Schleicher & Schuell). After cross-linking by ultraviolet irradiation (Stratalinker, Stratagene), the filters were hybridized to a 646-base pair (bp) BstXI/BamHI restriction fragment (positions 984-1629 of the open reading frame) of a human Cp cDNA labeled by random priming with [alpha -32P]dCTP. For Northern blot analyses of other genes, blots were hybridized with radiolabeled probes consisting of a 1.5-kb EcoRI fragment of human C-reactive protein cDNA (pCRP1, ATCC 59496), a 1.6-kb PstI fragment of human transferrin cDNA (TfR27A, ATCC 53106), a 525-bp fragment of human serum albumin generated by reverse transcription-PCR, and 0.65-bp EcoRI fragment of VEGF (provided by Bela Anand-Apte).

Construction of Vectors Containing Cp Promoter and Enhancer Segments-- Cp promoter/enhancer constructs, engineered to contain SacI and XhoI restriction sites, were made by PCR amplification using Pfu polymerase (Stratagene), primers containing these restriction sites, and a 4774-bp fragment of the 5'-flanking region of the human Cp gene as template (pGEM-Cp). pGEM-Cp was obtained by a PCR-based screen of a human genomic library in the bacterial artificial chromosome vector pBeloBAC11 (Research Genetics, Huntsville, AL) as described (34). A proximal construct was made from -848 to -1 (the nucleotide upstream of the translation-initiation site, which is here defined as +1) and ligated into SacI and XhoI sites of pGL3basic vector (Promega). For the long constructs inserted into pGL3basic, the PCR products from two separate amplification reactions were ligated to form a single construct. In brief, a proximal construct was made from -2389 (just upstream of an EcoRI site) to -1. Several distal constructs were PCR-amplified from 5'-termini at -4774, -3639, and -3576 to the 3'-terminus at -2325. The proximal and distal products were ligated at the EcoRI site and then into the 5'-SacI and 3'-XhoI sites upstream of luciferase in pGL3basic. An upstream Cp enhancer construct was made by PCR amplification of pGEM-Cp between -3639 and -3544 and was ligated into the SacI and XhoI sites of the pGL3prom vector (Promega) upstream of the SV40 promoter and luciferase. Site-directed mutagenesis of the Cp HRE in this construct (from CGT to AAA) was done by the megaprimer method (39). All constructs were verified by sequencing.

Transient Transfection of Cells and Reporter Gene Assays-- To measure transcriptional efficiency of chimeric Cp promoter/enhancer constructs, HepG2 cells at ~50% confluence in six-well plates were transiently transfected for 16 h with a reporter plasmid (2 µg) using Lipofectin (Invitrogen). To monitor transfection efficiency, a reporter gene construct (0.25 µg) containing beta -galactosidase behind an SV40 promoter was co-transfected. Transfected cells were allowed to recover for 6 h in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and then incubated with insulin or subjected to 1% O2 in serum-free medium for 18 h. Luciferase (Promega) and beta -galactosidase (Tropix, Bedford, MA) activities in cell extracts were determined by chemiluminescence.

Preparation of Nuclear Extracts-- Nuclear extracts were prepared from HepG2, Hepa-1c1c7, and Hepa c4 cells as described (40). Briefly, 1 × 108 cells were washed with ice-cold phosphate-buffered saline and then with a solution containing 10 mM Tris-HCl, pH 7.8, 1.5 mM MgCl2, and 10 mM KCl, supplemented with a protease inhibitor mixture containing 0.5 mM dithiothreitol, 0.4 mM phenylmethylsulfonyl fluoride, and 2 µg/ml each of leupeptin, pepstatin, and aprotinin (Sigma). After incubation on ice for 10 min, the cells were lysed by 10 strokes with a Dounce homogenizer and the nuclei were pelleted. The pellet was resuspended in a solution containing 420 mM KCl, 20 mM Tris-HCl, pH 7.8, 1.5 mM MgCl2, and 20% glycerol, supplemented with the protease mixture described above, and incubated at 4 °C with gentle agitation. The nuclear extract was centrifuged at 10,000 × g for 10 min, and the supernatant was dialyzed twice against a solution of 20 mM Tris-HCl, pH 7.8, 100 mM KCl, 0.2 mM EDTA, and 20% glycerol. Protein concentration was determined using the Bio-Rad reagent with bovine serum albumin as standard.

Electrophoretic Mobility Shift Assay (EMSA)-- Sequences of the sense strands of the oligonucleotide probes used for EMSA were as follows: 5'-TCT GTA CGT GAC CAC ACT CAC CTC-3' (Cp HRE), 5'-TCT GTA AAA GAC CAC ACT CAC CTC-3' (mutated Cp HRE), and 5'-GCC CTA CGT GCT GTC TCA CAC AGC-3' (erythropoietin HRE). The sense and antisense strands were annealed, gel-purified, and end-labeled with [gamma -32P]ATP (PerkinElmer Life Sciences) using T4-polynucleotide kinase (Promega). Unincorporated nucleotide was removed by gel filtration using G-25 Sephadex columns (Quick SpinTM TE, Roche Molecular Biochemicals). To measure DNA-protein interaction, 1 × 105 cpm of oligonucleotide probe was incubated with 5 µg of nuclear extract and 0.5 µg of sonicated, denatured salmon sperm DNA (Invitrogen) in 10 mM Tris-HCl, pH 7.8, 50 mM NaCl, 1 mM MgCl2, 1 mM EDTA, 5 mM dithiothreitol, and 5% glycerol, for 20 min at 4 °C in a total volume of 20 µl. The reaction mixture was subjected to electrophoresis (200 V in 0.3× Tris-buffered EDTA solution at 4 °C) using 5% nondenaturing polyacrylamide gels. Dried gels were subjected to autoradiography up to 24 h. For competition experiments, a 10-300-fold molar excess of unlabeled, annealed oligonucleotide was pre-mixed with radiolabeled probe before addition to the binding reaction. For gel supershift analysis, 1 µl of rabbit monoclonal antibody against HIF-1alpha or rabbit polyclonal antibody against ARNT/HIF-1beta (both from Novus Biologicals, Littleton, CO) was added after the initial 20-min incubation, and the solution was further incubated for 30 min at 4 °C before electrophoresis.

Statistical Analysis-- All experiments have been performed at least three times with similar results, and representative experiments are shown. Densitometric results are normalized with respect to internal controls and are expressed relative to the results in untreated control wells. Results from reporter experiments are expressed as mean values ± standard error of the mean (n = 3 replicate wells).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Induction of Cp Expression by Insulin-- We first determined whether insulin blocked the IL-6-mediated induction of Cp gene expression. Northern blot analysis of HepG2 cells showed that IL-6 increased the steady state level of both major Cp mRNA transcripts by more than 4-fold (Fig. 1A). The induction by IL-6 was substantially reduced by approximately half by insulin, to a level that was still 2-fold higher than untreated control cells. Surprisingly, Cp mRNA expression was increased by ~2-fold by insulin itself. A dose-response experiment was done to determine whether the inhibitory activity was observed at physiological concentrations of insulin (between 0.1 and 5 nM). Marked inhibition of IL-6-mediated Cp expression was observed at 0.3 nM insulin and maximal inhibition at ~1 nM (Fig. 1B). The average serum insulin concentration in fasting adults is ~0.1 nM, but insulin concentrations from 0.3 to 0.9 nM are transiently reached after meals (in normal adults and obese adults with impaired glucose tolerance, respectively), and levels of 1 nM and higher are seen after insulin administration and in patients with insulinomas (41, 42). The concentration of IL-6 used in this experiment, 2.5 ng/ml, is typical of the serum concentration in patients with acute inflammatory syndromes including bacteremia or meningitis (43). Thus, insulin has a dual activity with respect to Cp expression; it is a negative regulator of Cp under inflammatory conditions characterized by elevated IL-6, but it is a positive regulator under non-inflammatory conditions.


View larger version (37K):
[in this window]
[in a new window]
  		Fig. 1.   Positive and negative regulation of Cp expression by insulin. A, subconfluent HepG2 cells were incubated with medium alone (Cont.), IL-6 (25 ng/ml), insulin (Ins., 100 nM), or both for 18 h. Total RNA was isolated and Cp mRNA expression determined by Northern blot analysis using a radiolabeled, 646-bp Cp cDNA fragment as probe (upper panel). The 28 S ribosomal subunit was detected by ultraviolet irradiation and served as a loading control (middle panel). Cp mRNA expression was quantitated densitometrically, normalized by the 28 S subunit, and expressed with respect to untreated control cells (lower panel). B, HepG2 cells were incubated with IL-6 (2.5 ng/ml) in the presence of insulin at concentrations up to 100 nM for 18 h. Cp mRNA expression (upper panel), 28 S ribosomal subunit loading control (middle panel), and normalized Cp mRNA expression (lower panel) were determined as in A.

Northern blot analysis of HepG2 treated with increasing amounts of insulin showed that half-maximal stimulation of steady-state level of Cp mRNA occurred at ~1 nM insulin, and a maximal 4-fold increase was observed at 10 nM. (Fig. 2A). In multiple repetition of this experiment, the maximal stimulation of Cp mRNA expression by insulin was between 2- and 4-fold compared with untreated controls. Analysis of secreted Cp, by immunoblot analysis of conditioned medium, showed that the increase in synthesis and secretion of the protein nearly paralleled the induction of the transcript (Fig. 2B). Half-maximal induction was observed between 0.3 and 1 nM, and maximal stimulation was seen at 3-10 nM insulin. Cp was secreted entirely in the intact, 132-kDa form required for several of its biological activities (44, 45). The specificity of the induction of Cp was shown by Northern analysis of other secreted hepatic proteins. Insulin did not alter HepG2 cell mRNA expression of C-reactive protein, a positive acute phase protein, or albumin and transferrin, two negative acute phase proteins (Fig. 2C). In a positive control experiment, we measured the induction of VEGF gene expression as described previously for insulin (36) and insulin-like growth factor-1 (37); comparable inductions of VEGF and Cp mRNA were observed (Fig. 2C). A time-course experiment showed only marginal stimulation of Cp mRNA expression after 8 h, and essentially maximal expression by 16 h (Fig. 3A). A time course of protein secretion, as expected, showed delayed stimulation of Cp by insulin (Fig. 3B). Very little stimulation was seen after 16 h, but substantial stimulation by 24 h.


View larger version (51K):
[in this window]
[in a new window]
  		Fig. 2.   Induction of Cp synthesis in HepG2 cells in response to insulin. A, subconfluent HepG2 cells were incubated for 18 h with insulin at concentrations up to 100 nM. Cp mRNA expression (upper panel), 28 S ribosomal subunit loading control (middle panel), and normalized Cp mRNA expression (lower panel) were determined as in Fig. 1A. B, HepG2 cells were incubated with insulin at concentrations up to 100 nM for 18 h. Aliquots of conditioned medium were subjected to 7% SDS-PAGE followed by immunoblot analysis using polyclonal rabbit anti-human Cp IgG (top panel). The Coomassie Blue-stained gel was used as a loading control (middle panel). Cp secretion was quantitated densitometrically, normalized by the major, ~180-kDa band, and expressed compared with untreated control cells (lower panel). C, to determine specificity of the effect of insulin on Cp, the expression of several acute phase and other genes was determined. HepG2 cells were treated with insulin (100 nM) for 18 h and total RNA isolated. The expression of Cp, C-reactive protein (CRP), albumin, transferrin, and VEGF mRNA was determined by Northern blot analysis using gene-specific radiolabeled cDNA probes. Ultraviolet visualization of the 28 S ribosomal RNA subunit served as a control.


View larger version (42K):
[in this window]
[in a new window]
  		Fig. 3.   Time-course Cp induction in response to insulin. A, HepG2 cells were incubated with 30 or 100 nM insulin for up to 24 h. RNA was isolated and subjected to Northern blot analysis. Cp mRNA expression (upper panel), 28 S ribosomal subunit as loading control (middle panel), and normalized Cp mRNA expression (lower panel) were determined as in Fig. 1A. B, aliquots of conditioned media were subjected to 7% SDS-PAGE and immunoblot analysis using polyclonal rabbit anti-human Cp IgG (top panel). The amount of Cp was quantitated densitometrically and expressed as relative units (lower panel).

Transcriptional Activation of Cp by Insulin: Requirement for a HRE in the Cp 5'-Flanking Region-- We have previously reported that the Cp gene contains a functional HRE activated by both iron deficiency and hypoxia (34). This finding, coupled with recent reports that insulin induces multiple genes through activation of HIF-1 (36-38), led us to examine the possible role of HIF-1 in insulin-inducible Cp expression. We first compared the magnitude of the inductions in response to insulin and hypoxia. Exposure of cells to hypoxic conditions, i.e. 1% O2, induced an ~10-fold increase in Cp mRNA compared with normoxic control cells (range was between 6- and 19-fold in multiple experiments), an induction substantially greater than that by a maximal dose of insulin (2.6-fold in this experiment) (Fig. 4A). Exposure of cells to both hypoxia and insulin did not increase Cp expression beyond that induced by hypoxia alone, indicating the absence of a synergistic effect. Because the induction of HRE-containing genes by hypoxia requires new protein synthesis, we tested whether protein synthesis was also required for Cp induction by insulin. Cycloheximide completely blocked the induction of Cp, indicating a common dependence on new protein synthesis for both agonists (Fig. 4B).


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 4.   Comparison of Cp mRNA induction by insulin and hypoxia. A, subconfluent HepG2 cells were incubated with insulin (100 nM), or subjected to 1% O2 in a hypoxia chamber, or both, for 16 h. Cp mRNA expression (upper panel), 28 S ribosomal subunit loading control (middle panel), and normalized Cp mRNA expression (lower panel) were determined as in Fig. 1A. B, subconfluent HepG2 cells were pretreated with cycloheximide (CHX, 10 µg/ml) for 45 min and then with insulin (100 nM) for 16 h. Cp mRNA expression (upper panel), 28 S ribosomal subunit loading control (middle panel), and normalized Cp mRNA expression (lower panel) were determined as in Fig. 1A.

To investigate the molecular mechanism of insulin-stimulated Cp gene expression, we prepared chimeric constructs of the Cp gene 5'-flanking regulatory region ligated with luciferase as a heterologous reporter. The human Cp 5'-flanking region contains six consensus HIF-1 binding sites, i.e. (G/A)CGTG (35), arranged in three adjacent pairs between positions -4535 and -2447 (Fig. 5A). A series of promoter/enhancer fragments was constructed with progressively larger 5'-deletions, and the fragments were ligated upstream of luciferase in the promoterless reporter gene pGL3-basic. Subconfluent HepG2 cells were transiently transfected with these constructs and then incubated for 18 h with insulin or under hypoxic conditions. Transactivation of the entire 4774-bp construct (Cp-4774,-1-Luc) was increased ~3-fold by insulin (Fig. 5A). Hypoxia also transactivated this construct; the -fold stimulation was approximately twice that for insulin, consistent with their relative increases in Cp mRNA expression. Insulin and hypoxia similarly transactivated a chimeric construct (Cp-3639,-1-Luc) lacking the upstream-most pair of consensus HIF-1 binding sites. However, activation by insulin and hypoxia was completely abrogated in a promoter/enhancer construct lacking the three distal consensus HIF-1 binding sites (Cp-3576,-1-Luc). Basal activity was similar for all Cp promoter/enhancer constructs. These results suggest that a single HRE located between positions -3639 and -3577 is required for Cp transactivation by insulin and hypoxia.


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 5.   Determination of insulin-responsive element by deletion and mutation analysis of Cp gene 5'-flanking region. A, mapping of Cp gene insulin-responsive element by deletion analysis. Chimeric pGL3-basic vectors were constructed to contain the proximal 4774, 3639, or 3576 bp of the Cp gene 5'-flanking region (upstream of the translation initiation site) driving luciferase. Consensus HIF-1 binding sites in the linear maps are indicated by open rectangles, and labeled with the 5'-positions of the 5-bp G/ACGTG cores. The constructs were transiently transfected into subconfluent HepG2 cells (with a plasmid containing beta -galactosidase to correct for transfection efficiency) using Lipofectin. After recovery, the transfected cells were incubated with insulin (100 nM, black bars) for 18 h, or were subjected to hypoxic condition of 1% O2 for 18 h (striped bars), or were left untreated (open bars). Luciferase activity in cell extracts was measured and normalized for beta -galactosidase activity. B, analysis of HRE activity by site-directed mutation analysis. A segment of the Cp 5'-flanking region containing the putative HRE was ligated upstream of the SV40 promoter driving luciferase in pGL3-prom (Cp-3639,-3544-SV40-Luc). A second construct contained the same segment but with the core of the HIF-1 binding site mutated from CGT to AAA. The HIF-1 site is indicated by an open rectangle; the HIF-1 mutation is indicated by an X and by an underline below the mutated nucleotides. The constructs were transiently transfected (with a beta -galactosidase plasmid) into HepG2 cells as in A. After recovery the cells were incubated for 18 h with insulin (100 nM, black bars), or with 1% O2 (striped bars), or were left untreated (open bars). Luciferase activity in cell extracts was measured and normalized for beta -galactosidase activity.

To test whether this single HRE was sufficient for Cp transactivation by insulin, a mutagenesis strategy was used. A 96-bp segment containing this HRE was subcloned upstream of the SV40 promoter driving luciferase in the pGL3prom vector (Cp-3639,-3544-SV40-Luc). After transient transfection into HepG2 cells, insulin stimulated reporter gene expression by almost 3-fold (Fig. 5B). As before, the stimulation by hypoxia was approximately twice that by insulin. To show that the HRE in this enhancer region was responsible for the observed activation, the core 5'-ACGTG-3' sequence was mutated to 5'-AAAAG-3'. This construct was completely inactive with respect to transactivation by insulin or by hypoxia (Fig. 5B). These results suggest that a single HRE present in the Cp enhancer is necessary and sufficient for transactivation by insulin.

Relationship between Cp Promoter/Enhancer Sites Required for Stimulatory and Inhibitory Activities of Insulin-- We investigated the relationship between the cis-acting site at which insulin transactivates Cp and the site required for the inhibition of IL-6-mediated Cp transactivation. HepG2 cells were transfected with the full-length promoter/enhancer construct (Cp-4774,-1-Luc) and then were treated with IL-6, insulin, or both, and luciferase activity was measured. IL-6 induced reporter gene expression by almost 5-fold. Insulin reduced IL-6-mediated induction to the level seen with insulin alone, between 2- and 3-fold (Fig. 6A). Thus, both the positive and negative regulatory activities of insulin are reconstituted using the full-length Cp promoter/reporter construct. To determine whether the two activities of insulin utilize the same site, fragments of the 5'-flanking region were tested. The vector containing the 96-bp segment containing the active Cp HRE (Cp-3639,-3544-SV40-Luc) was transfected into HepG2 cells and treated with insulin and IL-6. As expected, insulin induced luciferase expression by ~2.5-fold; however, there was essentially no induction by IL-6 (Fig. 6B). The inability of insulin to inhibit the induction by IL-6 suggested that the inhibitory site was not in the region containing the HRE. Cells were then transfected with a construct containing the presumptive basal Cp promoter (Cp-848,-1-Luc), previously shown to drive constitutive, but not hypoxia-stimulated, reporter gene expression (34). As expected, insulin did not increase luciferase expression, but IL-6 increased expression by ~5-fold (Fig. 6C). The stimulatory activity of IL-6 was completely abrogated by insulin, indicating the presence of the site of negative regulation in this proximal construct. Together these results show that distinct cis-acting sites in the Cp gene 5'-flanking region are required for the stimulatory and inhibitory activities of insulin.


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 6.   Determination of domains of Cp gene 5'-flanking region responsible for the stimulatory and inhibitory actions of insulin. A, subconfluent HepG2 cell cultures were transiently transfected with a chimeric construct containing the proximal 4774 bp of the Cp gene 5'-flanking driving luciferase in pGL3-basic vector (Cp-4774,-1-Luc). The active HIF-1 binding site is indicated by an open rectangle and inactive sites indicated by X-marked rectangles. B, cells were transiently transfected a segment of the Cp 5'-flanking region containing the active HRE upstream of the SV40 promoter driving luciferase in pGL3-prom (Cp-3639,-3544-SV40-Luc). C, cells were transfected with a construct containing the proximal 848 bp of the Cp gene 5'-flanking driving luciferase in pGL3-basic vector (Cp-848,-1-Luc). All cells were co-transfected with a plasmid containing beta -galactosidase to correct for transfection efficiency. After recovery, the transfected cells were incubated for 18 h with insulin (100 nM), IL-6 (25 ng/ml), with both together, or with media alone. Luciferase activity in cell extracts was measured by chemiluminescence and normalized for beta -galactosidase activity.

Role of Hypoxia-inducible Factor-1 in Transcriptional Activation of Cp by Insulin-- To identify the transcription factor(s) involved in insulin-stimulated induction of Cp, EMSAs were done using a radiolabeled 24-bp Cp HRE probe. HepG2 cells were treated with insulin or hypoxia, and nuclear extracts were incubated with the Cp HRE probe. Treatment with insulin led to the formation of a single radiolabeled complex (Fig. 7A). The mobility of the complex induced by insulin was the same as that induced by hypoxia, and the same as that bound to an erythropoietin HRE probe, suggesting that a similar HIF-1-containing complex may be induced by both hypoxia and insulin. Competition experiments were done to show specificity of binding of the complex to the Cp HRE probe. The binding of radiolabeled Cp HRE probe was partially competed by a 10-fold molar excess of unlabeled Cp HRE and almost completely competed by a 100-fold molar excess (Fig. 7B). Binding was similarly blocked by an excess of unlabeled erythropoietin HRE probe, whereas a mutated Cp HRE probe showed only partial competition even at 300-fold molar excess.


View larger version (57K):
[in this window]
[in a new window]
  		Fig. 7.   Specific binding of an insulin-stimulated transcription factor complex to the Cp HRE. A, EMSAs were done to determine Cp HRE-binding complexes. HepG2 cells were treated for 8 h with insulin (Ins., 100 nM) or with 1% O2 (Hpx.). Nuclear extracts were mixed with a 32P-labeled, double-stranded 24-mer probe containing either the Cp HRE or the erythropoietin (Epo) HRE. Probe-bound complexes were resolved by 5% nondenaturing PAGE and visualized by autoradiography. Cont., control. The positions of the putative HIF-1 and constitutive (Const.) complexes are indicated by arrows. B, competitor binding to show specificity of binding of a complex to the Cp HRE. HepG2 cells were treated with insulin (100 nM) for 16 h and nuclear extracts prepared. Radiolabeled probe was pre-mixed with unlabeled, annealed, 24-mer oligonucleotide competitor at 10-, 100-, or 300-fold molar excess (increasing concentration is indicated by upward slope of triangle) before addition to the nuclear extracts. The competitor probes were wild-type (wt) Cp HRE, mutant (mut) Cp HRE containing a CGT-to-AAA mutation (underlined), and erythropoietin (Epo) HRE. The extracts were mixed with a 32P-labeled probe containing the Cp HRE, and probe-bound complexes identified as in A.

Gel supershift studies were done to confirm the presence of HIF-1 in the insulin-induced complex that binds the Cp HRE. Rabbit monoclonal anti-HIF-1alpha shifted the complex formed in insulin-treated cells (Fig. 8A). Furthermore, a polyclonal antibody against ARNT/HIF-1beta (and a mixture of both antibodies) completely blocked the formation of the complex. To further confirm the requirement for HIF-1 in the formation of insulin-stimulated, Cp HRE-binding complexes, we took advantage of the Hepa c4 mouse hepatoma cell line, which is deficient in ARNT/HIF-1beta (46). These cells, derived from the parental Hepa-1c1c7 cell line, have been used to show the requirement for HIF-1 in gene transactivation by hypoxia (40), and more recently by insulin (36). Both cell lines were transfected with the chimeric reporter gene Cp-3639,-3544-SV40-Luc. Treatment of the wild-type Hepa-1c1c7 cells with insulin increased luciferase expression by almost 2-fold, whereas the stimulation by hypoxia was ~3-fold (Fig. 8B). Neither treatment increased Cp enhancer activity in the HIF-1-beta -deficient cell line. The mouse cell lines were also used to establish HIF-1 binding by electrophoretic mobility shift assay. Hepa-1c1c7 and c4 cells were treated with insulin or with CoCl2, and the binding of the HIF-1 complex to the Cp HRE probe was determined; we previously showed that CoCl2, like hypoxia, activated HIF-1 and Cp transcription in these cells (34). Inducible binding was observed in nuclear extracts of wild-type Hepa-1c1c7 cells treated with either agonist, whereas essentially no HIF-1 binding was seen in the ARNT/HIF-1beta -deficient Hepa c4 cells (Fig. 8C). Together, these studies clearly demonstrate the requirement for HIF-1 in activation of Cp transcription by insulin.


View larger version (42K):
[in this window]
[in a new window]
  		Fig. 8.   Role of HIF-1 in insulin-stimulated activation of the Cp promoter/enhancer. A, identification of HIF-1 by supershift analysis. HepG2 cells were incubated in the absence (Cont.) or presence of insulin (100 nM) for 8 h and nuclear extracts prepared. The extracts were incubated with a 32P-labeled, 24-mer Cp HRE probe in the presence of 1 µl of anti-HIF-1alpha , anti-HIF-1beta , or both for 20 min. The extracts were subjected to 5% nondenaturing PAGE and autoradiography. The positions of the HIF-1 and constitutive (Const.) complexes are indicated by arrows. The supershifted complex is indicated by an open arrow. B, Cp enhancer activity in HIF-1beta /ARNT-deficient cells. The chimeric reporter gene Cp-3639,-3544-SV40-Luc was transiently transfected (with a beta -galactosidase plasmid) into wild-type Hepa-1c1c7 and HIF-1beta /ARNT-deficient Hepa c4 cells. After recovery the cells were incubated for 18 h with insulin (100 nM, black bars) or with 1% O2 (striped bars), or were left untreated (open bars). Luciferase activity in cell extracts was measured and normalized for beta -galactosidase activity. C, analysis of transcription factor complex formation in HIF-1beta /ARNT-deficient cells. Mouse wild-type Hepa-1c1c7 and HIF-1beta /ARNT-deficient Hepa c4 cells were incubated with insulin (100 nM, Ins.) or CoCl2 (0.1 mM) for 10 h. Nuclear extracts were incubated with a 32P-labeled, 24-mer Cp HRE probe and HRE-bound complexes detected by nondenaturing polyacrylamide gel electrophoresis and autoradiography as in A.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have found that the effect of insulin on hepatic cell transcription of Cp depends on the inflammatory state of the cell. In the absence of a pro-inflammatory stimulus, i.e. treatment with IL-6, insulin enhances Cp gene expression and protein production in HepG2 cells. This induction requires activation of HIF-1 and binding to an HRE in the distal 5'-flanking region of Cp. In contrast, in the presence of IL-6, insulin markedly represses Cp gene expression in these cells. Thus, insulin functions as a bidirectional, condition-dependent regulator of hepatic cell Cp expression.

Negative Regulation of Cp Transcription by Insulin-- We have confirmed previous reports of induction of Cp in hepatoma cells by IL-6 (31, 32). Our finding that IL-6 increases the steady-state level of Cp mRNA and activates a chimeric Cp promoter-Luc reporter shows that regulation is at the level of transcription. Although these results are consistent with the mechanism of IL-6-mediated induction of other acute phase genes, transcriptional regulation of Cp by IL-6 has not been previously shown. We cannot account for the difference between our results and an earlier report that Cp induction by IL-6 is primarily post-transcriptional, but a variance in culture conditions is a possible explanation (33). Elucidation of the mechanism of transcriptional activation of acute phase genes by IL-6 is an area of intense investigation. An important role for C/EBPbeta in IL-6-stimulated transactivation of multiple acute phase genes has been shown by up-regulation of C/EBPbeta expression, and by its binding to specific sequences in the 5'-flanking regions of these genes (47-49). More recently, the IL-6-activated "acute phase response factor" has been shown to be STAT3, which binds to palindromic, TT(N)5AA motifs (termed acute phase response elements) in the promoters of multiple (but not all (Ref. 50)) acute phase genes (51-54). The essential role of STAT3 in the acute phase response in vivo has been shown in mice with an inducible STAT3 gene deletion (55). The molecular mechanism of Cp transactivation by IL-6 has not been investigated in detail. Binding of C/EBPbeta to the rat Cp promoter has been shown, but agonist-induced responses have not been examined (56). Likewise, the role of STAT3 in basal or agonist-induced Cp transcription has not been reported; however, the presence of three near-consensus STAT3-binding sites in the proximal Cp promoter between nucleotide positions -848 and -1 merits further analysis.

Our results show that insulin suppresses the IL-6-mediated increase in Cp mRNA level to nearly the same level as that seen with insulin alone. The experiments with a chimeric reporter gene (Cp-848,-1-Luc) confirm that IL-6 transcriptional activity is completely blocked by insulin. Thus, Cp joins a family of insulin-inhibited acute phase genes including haptoglobin, thiostatin, complement C3, and C-reactive protein (6, 11). The negative regulation by insulin may be mediated by at least three pathways. Insulin reduces IL-6-induced STAT-3 activity as measured by gene transcription, mRNA accumulation, protein concentration, and DNA binding activity (7). Insulin also reduces the expression of the IL-6 receptor alpha -subunit and IL-6 receptor binding (7). Finally, insulin suppresses transactivation by C/EBPbeta (8). The presence of an active C/EBPbeta -binding site in the rat Cp promoter (56) and the consensus STAT3-binding sites suggest that either or both of these pathways may be involved. Our results indicate that the direction and magnitude of the response of the Cp promoter to insulin is condition-dependent; under normal physiological conditions, insulin increases Cp transcription, whereas, during the systemic acute phase response or localized inflammation, insulin reduces Cp transcription. We are not aware of other acute phase reactants that are transcriptionally activated by insulin; thus, the response of Cp may be unique. The dual response of Cp to insulin may reflect its pleiotropic nature, with possibly distinct functions in inflammation and iron homeostasis. Suppressive activities of insulin have been reported in other enzyme systems, e.g. it inhibits transcriptional activation of fructose-2,6-bisphosphatase by dexamethasone in rat hepatoma FTO-2B cells (57). Insulin by itself causes transcriptional activation of this enzyme in hepatic FAO-1 (58). Thus, the function of insulin may be bidirectional in this system as well; however, a direct demonstration using a single type of cell has not been demonstrated.

Activation of Cp Transcription by Insulin-- We observed a 2-5-fold insulin-stimulated increase in Cp transcription, in Cp mRNA level, and in the rate of Cp secretion in HepG2 cells. We also found that the stimulation of Cp gene expression by a maximal concentration of insulin was much lower than that seen upon treatment with 1% O2. Our observations are comparable with a previous report of 2- and 4-fold induction of aldolase A transcription in HepG2 cells by insulin and hypoxia, respectively (36). The differential expression may reflect the 2-fold higher level of HIF-1alpha in cells treated with hypoxia compared with cells treated with insulin (59); however, these results were obtained in embryonic kidney 293 cells, and cell type-specific differences in HIF-1alpha activation by insulin have been observed (36). The mechanism(s) of HIF-1alpha induction by hypoxia and by insulin is not clearly understood. Hypoxia increases the amount of HIF-1alpha by stabilization of the protein (60). Under normoxic conditions, rapid, ubiquitin-dependent degradation of HIF-1alpha occurs, whereas hypoxic stress inhibits this process (61). There is evidence that insulin utilizes a similar mechanism for stabilization of HIF-1alpha (36). Recent reports suggest that HIF-1alpha activation by both hypoxia and insulin utilize the phosphatidylinositol 3-kinase pathway (62, 63).

Role of Insulin in Regulating Cp Levels in Vivo-- Our results may help to clarify contradictory studies on Cp expression in diabetic patients and in animal models of diabetes. Elevated plasma Cp levels have been reported in non-insulin-dependent diabetes mellitus (NIDDM, type II diabetes) (64-66), but normal Cp levels have been reported as well (67, 68). The reports on insulin-dependent diabetes mellitus (IDDM, type I diabetes) are similarly inconclusive, with one report indicating decreased plasma Cp (69), whereas others indicate increased Cp (70). The lack of a consistent response of serum Cp to diabetes has been ascribed to variability in the acute phase response (64), diabetic vascular complications (71), oxidative stress (70), extent of hyperglycemia (66), serum nitric oxide (72), and to methodological differences (70).

Our in vitro results suggest that the circulating level of insulin may be a critical regulator of hepatic Cp synthesis, and consequently, plasma Cp level. In this case, part of the variation in Cp levels in NIDDM patients may be a result of the large range in plasma insulin values from normal to very high (e.g. in early phases of the disease and in diabetes related to obesity), and possibly of the oscillatory nature of insulin levels in NIDDM. IDDM patients require insulin for survival, and thus the method and extent of diabetic control may influence Cp status. Animal models of diabetes provide additional insights. In both alloxan- and streptozotocin-induced diabetic rats, the decrease in insulin level is accompanied by substantial reductions in plasma Cp (73-75), and treatment of diabetic rats with insulin restores plasma Cp to normal levels (75). Similarly, treatment of rats with streptozotocin decreases Cp synthesis by the isolated perfused liver, but is restored to normal after treatment of the rats with insulin (76). Taken together, these data suggest a possible regulatory activity of insulin on hepatic Cp synthesis and Cp plasma concentration in vivo. Our results suggest that the relationship between plasma Cp and diabetes is likely to be a complex function including dependences on both insulin levels and the extent of inflammation.

    ACKNOWLEDGEMENTS

We are grateful to Oliver Hankinson for the generous gift of mouse hepatoma Hepa-1c1c7 and the variant Hepa c4 cells and to Bela Anand-Apte for a VEGF cDNA probe.

    FOOTNOTES

* This work was supported by a fellowship from the American Heart Association of Northeast Ohio (to C. K. M.) and by National Institutes of Health Grants HL29582 and HL67725 (to P. L. F.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Dept. of Cell Biology, Lerner Research Inst., Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-444-8053; Fax: 216-444-9404; E-mail: foxp@ccf.org.

Published, JBC Papers in Press, May 23, 2002, DOI 10.1074/jbc.M203610200

    ABBREVIATIONS

The abbreviations used are: IL, interleukin; ARNT, aryl hydrocarbon receptor nuclear translocator; C/EBP, CCAAT/enhancer-binding protein; Cp, ceruloplasmin; EMSA, electrophoretic mobility shift assay; HIF, hypoxia-inducible factor; HRE, hypoxia-responsive element; IDDM, insulin-dependent diabetes mellitus; Luc, luciferase; NIDDM, non-insulin-dependent diabetes mellitus; STAT, signal transducers and activators of transcription; VEGF, vascular endothelial growth factor.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Gabay, C., and Kushner, I. (1999) N. Engl. J. Med. 340, 448-454[Free Full Text]
2. Baumann, H., and Gauldie, J. (1994) Immunol. Today 15, 74-80[CrossRef][Medline] [Order article via Infotrieve]
3. Heinrich, P. C., Castell, J. V., and Andus, T. (1990) Biochem. J. 265, 621-636[Medline] [Order article via Infotrieve]
4. Thompson, D., Harrison, S. P., Evans, S. W., and Whicher, J. T. (1991) Cytokine 3, 619-626[CrossRef][Medline] [Order article via Infotrieve]
5. Campos, S. P., and Baumann, H. (1992) Mol. Cell. Biol. 12, 1789-1797[Abstract/Free Full Text]
6. O'Riordain, M. G., Ross, J. A., Fearon, K. C., Maingay, J., Farouk, M., Garden, O. J., and Carter, D. C. (1995) Am. J. Physiol. 269, E323-E330[Medline] [Order article via Infotrieve]
7. Campos, S. P., Wang, Y., and Baumann, H. (1996) J. Biol. Chem. 271, 24418-24424[Abstract/Free Full Text]
8. Guo, S., Cichy, S. B., He, X., Yang, Q., Ragland, M., Ghosh, A. K., Johnson, P. F., and Unterman, T. G. (2001) J. Biol. Chem. 276, 8516-8523[Abstract/Free Full Text]
9. De Feo, P., Volpi, E., Lucidi, P., Cruciani, G., Reboldi, G., Siepi, D., Mannarino, E., Santeusanio, F., Brunetti, P., and Bolli, G. B. (1993) Diabetes 42, 995-1002[Abstract]
10. Yudkin, J. S., Panahloo, A., Stehouwer, C., Emeis, J. J., Bulmer, K., Mohamed-Ali, V., and Denver, A. E. (2000) Diabetologia 43, 1099-1106[CrossRef][Medline] [Order article via Infotrieve]
11. Campos, S. P., Wang, Y., Koj, A., and Baumann, H. (1994) Cytokine 6, 485-492[CrossRef][Medline] [Order article via Infotrieve]
12. Kushner, I. (1988) Methods Enzymol. 163, 373-383[Medline] [Order article via Infotrieve]
13. Samokyszyn, V. M., Miller, D. M., Reif, D. W., and Aust, S. D. (1989) J. Biol. Chem. 264, 21-26[Abstract/Free Full Text]
14. Mukhopadhyay, C. K., Mazumder, B., Lindley, P. F., and Fox, P. L. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11546-11551[Abstract/Free Full Text]
15. Lamb, D. J., and Leake, D. S. (1994) FEBS Lett. 338, 122-126[CrossRef][Medline] [Order article via Infotrieve]
16. Van Lenten, B. J., Hama, S. Y., De, Beer, F. C., Stafforini, D. M., McIntyre, T. M., Prescott, S. M., La Du, B. N., Fogelman, A. M., and Navab, M. (1995) J. Clin. Invest. 96, 2758-2767[Medline] [Order article via Infotrieve]
17. Osaki, S. (1966) J. Biol. Chem. 241, 5053-5059[Abstract/Free Full Text]
18. Miyajima, H., Nishimura, Y., Mizoguchi, K., Sakamoto, M., Shimizu, T., and Honda, N. (1987) Neurology 37, 761-767[Abstract/Free Full Text]
19. Harris, Z. L., Durley, A. P., Man, T. K., and Gitlin, J. D. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 10812-10817[Abstract/Free Full Text]
20. Osaki, S., and Johnson, D. A. (1969) J. Biol. Chem. 244, 5757-5765[Abstract/Free Full Text]
21. Ragan, H. A., Nacht, S., Lee, G. R., Bishop, C. R., and Cartwright, G. E. (1969) Am. J. Physiol. 217, 1320-1323[Free Full Text]
22. Mukhopadhyay, C. K., Attieh, Z. K., and Fox, P. L. (1998) Science 279, 714-717[Abstract/Free Full Text]
23. Attieh, Z. K., Mukhopadhyay, C. K., Seshadri, V., Tripoulas, N. A., and Fox, P. L. (1999) J. Biol. Chem. 274, 1116-1123[Abstract/Free Full Text]
24. Xie, J. X., Tsoi, Y. K., Chang, Y. Z., Ke, Y., and Qian, Z. M. (2002) Mol. Brain Res. 99, 12-16[Medline] [Order article via Infotrieve]
25. Qian, Z. M., Tsoi, Y. K., Ke, Y., and Wong, M. S. (2001) Exp. Brain Res. 140, 369-374[CrossRef][Medline] [Order article via Infotrieve]
26. Askwith, C., Eide, D., Van Ho, A., Bernard, P. S., Li, L., Davis-Kaplan, S., Sipe, D. M., and Kaplan, J. (1994) Cell 76, 403-410[CrossRef][Medline] [Order article via Infotrieve]
27. Stearman, R., Yuan, D. S., Yamaguchi-Iwai, Y., Klausner, R. D., and Dancis, A. (1996) Science 271, 1552-1557[Abstract]
28. Ryffel, B., Car, B. D., Woerly, G., Weber, M., DiPadova, F., Kammuller, M., Klug, S., Neubert, R., and Neubert, D. (1994) Blood 83, 2093-2102[Abstract/Free Full Text]
29. Gitlin, J. D. (1988) J. Biol. Chem. 263, 6281-6287[Abstract/Free Full Text]
30. Beaumier, D. L., Caldwell, M. A., and Holbein, B. E. (1984) Infect. Immun. 46, 489-494[Abstract/Free Full Text]
31. Mackiewicz, A., and Kushner, I. (1989) Scand. J. Immunol. 29, 265-271[CrossRef][Medline] [Order article via Infotrieve]
32. Ramadori, G., Van Damme, J., Rieder, H., and Meyer zum Büschenfelde, K.-H. (1988) Eur. J. Immunol. 18, 1259-1264[Medline] [Order article via Infotrieve]
33. Daffada, A. A., and Young, S. P. (1999) FEBS Lett. 457, 214-218[CrossRef][Medline] [Order article via Infotrieve]
34. Mukhopadhyay, C. K., Mazumder, B., and Fox, P. L. (2000) J. Biol. Chem. 275, 21048-21054[Abstract/Free Full Text]
35. Semenza, G. L. (1999) Annu. Rev. Cell Dev. Biol. 15, 551-578[CrossRef][Medline] [Order article via Infotrieve]
36. Zelzer, E., Levy, Y., Kahana, C., Shilo, B. Z., Rubinstein, M., and Cohen, B. (1998) EMBO J. 17, 5085-5094[CrossRef][Medline] [Order article via Infotrieve]
37. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., Stokoe, D., and Giaccia, A. J. (2000) Genes Dev. 14, 391-396[Abstract/Free Full Text]
38. Masuda, S., Chikuma, M., and Sasaki, R. (1997) Brain Res. 746, 63-70[CrossRef][Medline] [Order article via Infotrieve]
39. Barik, S. (1993) Methods Mol. Biol. 15, 277-286
40. Rolfs, A., Kvietikova, I., Gassmann, M., and Wenger, R. H. (1997) J. Biol. Chem. 272, 20055-20062[Abstract/Free Full Text]
41. Service, F. J., O'Brien, P. C., McMahon, M. M., and Kao, P. C. (1993) J. Clin. Endocrinol. Metab. 76, 655-659[Abstract]
42. Reaven, G. M., Chen, Y. D., Hollenbeck, C. B., Sheu, W. H., Ostrega, D., and Polonsky, K. S. (1993) J. Clin. Endocrinol. Metab. 76, 44-48[Abstract]
43. Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., and Espevik, T. (1989) J. Exp. Med. 169, 333-338[Abstract/Free Full Text]
44. Ehrenwald, E., Chisolm, G. M., and Fox, P. L. (1994) J. Clin. Invest. 93, 1493-1501[Medline] [Order article via Infotrieve]
45. Van Eden, M. E., and Aust, S. D. (2000) Arch. Biochem. Biophys. 381, 119-126[CrossRef][Medline] [Order article via Infotrieve]
46. Wood, S. M., Gleadle, J. M., Pugh, C. W., Hankinson, O., and Ratcliffe, P. J. (1996) J. Biol. Chem. 271, 15117-15123[Abstract/Free Full Text]
47. Poli, V., Mancini, F. P., and Cortese, R. (1990) Cell 63, 643-653[CrossRef][Medline] [Order article via Infotrieve]
48. Baumann, H., Morella, K. K., Campos, S. P., Cao, Z., and Jahreis, G. P. (1992) J. Biol. Chem. 267, 19744-19751[Abstract/Free Full Text]
49. Agrawal, A., Cha-Molstad, H., Samols, D., and Kushner, I. (2001) J. Immunol. 166, 2378-2384[Abstract/Free Full Text]
50. Niehof, M., Streetz, K., Rakemann, T., Bischoff, S. C., Manns, M. P., Horn, F., and Trautwein, C. (2001) J. Biol. Chem. 276, 9016-9027[Abstract/Free Full Text]
51. Zhang, D., Sun, M., Samols, D., and Kushner, I. (1996) J. Biol. Chem. 271, 9503-9509[Abstract/Free Full Text]
52. Wegenka, U. M., Lütticken, C., Buschmann, J., Yuan, J., Lottspeich, F., Müller-Esterl, W., Schindler, C., Roeb, E., Heinrich, P. C., and Horn, F. (1994) Mol. Cell. Biol. 14, 3186-3196[Abstract/Free Full Text]
53. Ripperger, J. A., Fritz, S., Richter, K., Hocke, G. M., Lottspeich, F., and Fey, G. H. (1995) J. Biol. Chem. 270, 29998-30006[Abstract/Free Full Text]
54. Akira, S., Nishio, Y., Inoue, M., Wang, X. J., Wei, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., and Kishimoto, T. (1994) Cell 77, 63-71[CrossRef][Medline] [Order article via Infotrieve]
55. Alonzi, T., Maritano, D., Gorgoni, B., Rizzuto, G., Libert, C., and Poli, V. (2001) Mol. Cell. Biol. 21, 1621-1632[Abstract/Free Full Text]
56. Bingle, C. D., Fleming, R. E., and Gitlin, J. D. (1993) Biochem. J. 294, 473-479[Medline] [Order article via Infotrieve]
57. Lemaigre, F. P., Lause, P., and Rousseau, G. G. (1994) FEBS Lett. 340, 221-225[CrossRef][Medline] [Order article via Infotrieve]
58. Espinet, C., Vargas, A. M., el-Maghrabi, M. R., Lange, A. J., and Pilkis, S. J. (1993) Biochem. J. 293, 173-179[Medline] [Order article via Infotrieve]
59. Feldser, D., Agani, F., Iyer, N. V., Pak, B., Ferreira, G., and Semenza, G. L. (1999) Cancer Res. 59, 3915-3918[Abstract/Free Full Text]
60. Huang, L. E., Arany, Z., Livingston, D. M., and Bunn, H. F. (1996) J. Biol. Chem. 271, 32253-32259[Abstract/Free Full Text]
61. Salceda, S., and Caro, J. (1997) J. Biol. Chem. 272, 22642-22647[Abstract/Free Full Text]
62. Stiehl, D. P., Jelkmann, W., Wenger, R. H., and Hellwig-Burgel, T. (2002) FEBS Lett. 512, 157-162[CrossRef][Medline] [Order article via Infotrieve]
63. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., and Vogt, P. K. (2001) Cell Growth Differ. 12, 363-369[Abstract/Free Full Text]
64. McMillan, D. E. (1989) Metabolism 38, 1042-1046[CrossRef][Medline] [Order article via Infotrieve]
65. Jones, A. F., Winkles, J. W., Jennings, P. E., Florkowski, C. M., Lunec, J., and Barnett, A. H. (1988) Diabetes Res. 7, 89-92[Medline] [Order article via Infotrieve]
66. Daimon, M., Susa, S., Yamatani, K., Manaka, H., Hama, K., Kimura, M., Ohnuma, H., and Kato, T. (1998) Diabetes Care 21, 1525-1528[Abstract]
67. Cheta, D., Mihalache, N., Santu, E., and Mincu, I. (1981) Rev. Roum. Méd. Int. 19, 55-61
68. Collier, A., Wilson, R., Bradley, H., Thomson, J. A., and Small, M. (1990) Diabet. Med. 7, 27-30[Medline] [Order article via Infotrieve]
69. Awadallah, R., El-, Dessoukey, E. A., Doss, H., Khalifa, K., and el-Hawary, Z. (1978) Z. Ernahrungswiss 17, 79-83[CrossRef][Medline] [Order article via Infotrieve]
70. Cunningham, J., Leffell, M., Mearkle, P., and Harmatz, P. (1995) Metabolism 44, 996-999[CrossRef][Medline] [Order article via Infotrieve]
71. Jonsson, A., and Wales, J. K. (1976) Diabetologia 12, 245-250[CrossRef][Medline] [Order article via Infotrieve]
72. Daimon, M., Sugiyama, K., Saitoh, T., Yamaguchi, H., Hirata, A., Ohnuma, H., Igarashi, M., Eguchi, H., Manaka, H., and Kato, T. (2000) Diabetes Care 23, 559-560[Medline] [Order article via Infotrieve]
73. Novelli, E. L., Rodrigues, N. L., and Ribas, B. O. (1988) Can. J. Physiol. Pharmacol. 66, 663-665[Medline] [Order article via Infotrieve]
74. Asayama, K., Nakane, T., Uchida, N., Hayashibe, H., Dobashi, K., and Nakazawa, S. (1994) Horm. Metab. Res. 26, 313-315[Medline] [Order article via Infotrieve]
75. Mohan, I. K., and Das, U. N. (1998) Free Radical Biol. Med. 25, 757-765[CrossRef][Medline] [Order article via Infotrieve]
76. Miller, L. L., Treat, D. E., Fridd, B., and Wemett, D. (1990) Hepatology 11, 635-645[Medline] [Order article via Infotrieve]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
N. Tapryal, C. Mukhopadhyay, D. Das, P. L. Fox, and C. K. Mukhopadhyay
Reactive Oxygen Species Regulate Ceruloplasmin by a Novel mRNA Decay Mechanism Involving Its 3'-Untranslated Region: IMPLICATIONS IN NEURODEGENERATIVE DISEASES
J. Biol. Chem., January 16, 2009; 284(3): 1873 - 1883.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. E. Wiggins, M. Goyal, B. L. Wharram, and R. C. Wiggins
Antioxidant Ceruloplasmin Is Expressed by Glomerular Parietal Epithelial Cells and Secreted into Urine in Association with Glomerular Aging and High-Calorie Diet
J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1382 - 1387.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
L. Visser, C. J. Zuurbier, F. J. Hoek, B. C. Opmeer, E. de Jonge, B. A. J. M. de Mol, and H. B. van Wezel
Glucose, insulin and potassium applied as perioperative hyperinsulinaemic normoglycaemic clamp: effects on inflammatory response during coronary artery surgery
Br. J. Anaesth., October 1, 2005; 95(4): 448 - 457.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Sarkar, V. Seshadri, N. A. Tripoulas, M. E. Ketterer, and P. L. Fox
Role of Ceruloplasmin in Macrophage Iron Efflux during Hypoxia
J. Biol. Chem., November 7, 2003; 278(45): 44018 - 44024.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/31/27903    most recent
M203610200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seshadri, V.
Right arrow Articles by Mukhopadhyay, C. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seshadri, V.
Right arrow Articles by Mukhopadhyay, C. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement